Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

Multicenter Phase II Trial of Fludarabine and Cyclophosphamide in Combination With Alemtuzumab (FC-Cam) for Patients With Relapsed Chronic Lymphocytic Leukemia - CLL-2L Protocol of the German CLL-Study Group (GCLLSG)

This study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed B-cell chronic lymphatic leukemia.

Inclusion Criteria:

• B-CLL in need of treatment
• One or two prior prior therapies
• WHO performance status 0-2

Exclusion Criteria:

• Serum creatinine > 1.5 ULN
• Major organ dysfunctions
• Pregnant or nursing